All In Biotech

NDA 209531 · Biogen

Spinraza

Nusinersen Sodium · Intrathecal · Survival Motor Neuron-2-directed RNA Interaction; Antisense Oligonucleotide

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Dec 23, 2016

Approved uses

4

Original approval plus efficacy supplements

Registered trials

23

8 Phase 3, 4 recruiting

FAERS reports

7,888

3,872 serious, 798 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 31, 2026.

SPINRAZA is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. SPINRAZA is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients ( 1 )

Mechanism: SPINRAZA is an antisense oligonucleotide (ASO) designed to treat SMA caused by mutations in chromosome 5q that lead to SMN protein deficiency. Using in vitro assays and studies in transgenic animal models of SMA, SPINRAZA was shown to increase exon 7 inclusion in SMN2 messenger ribonucleic acid (mRNA) transcripts and production of full-length SMN protein.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 27, 2026 Supplement 16 · Efficacy OrphanLabelLetter
  • Jun 16, 2020 Supplement 10 · Efficacy OrphanLetterLabel
  • May 14, 2018 Supplement 3 · Efficacy OrphanLetterLabel
  • Dec 23, 2016 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
3 products under this application
  • SPINRAZA · NUSINERSEN SODIUM EQ 50MG BASE/5ML (EQ 10MG BASE/ML) · SOLUTION, INTRATHECAL · Prescription
  • SPINRAZA · NUSINERSEN SODIUM EQ 12MG BASE/5ML (EQ 2.4MG BASE/ML) · SOLUTION, INTRATHECAL · Prescription
  • SPINRAZA · NUSINERSEN SODIUM EQ 28MG BASE/5ML (EQ 5.6MG BASE/ML) · SOLUTION, INTRATHECAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Nusinersen" as an intervention, any sponsor and status, largest first.

All 23 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • headache578
  • post lumbar puncture syndrome524
  • pyrexia410
  • procedural pain386
  • pneumonia371
  • death339
  • vomiting315
  • asthenia302
  • back pain265
  • fatigue253
  • scoliosis230
  • fall186

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20161
2017637
20181,223
2019945
2020800
2021958
2022801
2023729
2024624
2025594
2026576

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Spinraza (Nusinersen Sodium/PF)

2024 spending

$3.4M

Beneficiaries

n/a

24 claims

Per beneficiary

n/a

$28,221.54 per unit

View as table
YearSpending
2020$5,622,217
2021$2,782,478
2022$2,632,872
2023$3,116,508
2024$3,386,585

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 65 on PubMed

Sponsor: Biogen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.